MedTrace Logo

Capsaicin-induced Muscle Pain in Humans

NCT02377180 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2017-01-18

No results posted yet for this study

Summary

There is currently no specific diagnostic test for primary muscular pain. The present study investigates whether selective blockade of the suprascapular nerve can effectively abolish experimental pain arising from the supraspinatus muscle. Experimental muscle pain is induced by intramuscular injection of capsaicin, an alkaloid from red chili peppers. The study consists of three parts:

1. to describe the development, time course and intensity of capsaicin-induced muscle pain
2. to evaluate the effectiveness of suprascapular nerve block against capsaicin-induced muscle pain
3. to compare suprascapular nerve block and direct intramuscular local anesthetic infiltration for their effectiveness in capsaicin-induced muscle pain

Conditions

  • Healthy

Interventions

PROCEDURE

Intramuscular capsaicin injection

Intramuscular injection of capsaicin: 50 mcg/0.5 ml

PROCEDURE

Suprascapular nerve block

Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus or trapezius muscle in randomized order, followed by suprascapular nerve block (ultrasound-guided) using Lidocaine 1%; nerve block is expected to be effective only in pain arising from the supraspinatus muscle. Trapezius pain serves as control condition. Evaluates the diagnostic validity of suprascapular nerve block for muscle pain.

PROCEDURE

Local anesthetic infiltration

Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus muscle in two different sessions; suprascapular nerve block in one session and intramuscular local anesthetic infiltration in one session (in randomized order) using Lidocaine 1%; the aim is to investigate which procedure provides faster and more efficient pain relief. Compares effectivity of suprascapular nerve block vs. intramuscular local anesthetic infiltration.

Sponsors & Collaborators

  • Aalborg University

    collaborator OTHER

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Michele Curatolo, M.D., Ph.D. · Department of Anesthesiology and Pain Therapy, University of Washington, Seattle WA, USA

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02377180 on ClinicalTrials.gov